30-09-2022 13:00 via wallstreet-online.de

Ainos Announces Positive Results from Additional Preclinical Study of Its Low-dose Oral Interferon Formulation Against New Variant Virus - Omicron

VELDONA® formulation showed significant stabilization of physical condition and complete recovery from lung inflammation throughout the course of treatment period.By upregulation of immunomodulatory, Ainos' VELDONA® formulation demonstrates efficacy …
Weiterlesen »